EUCTR2017-000244-18-IT进行中（未招募）1 期
A randomized, placebo-controlled, double-blind, parallel-group, multicenter,exploratory dose-response study to assess the efficacy and safetyof different oral doses of BAY 1128688 in women with symptomaticendometriosis over a 12-week treatment period - Akrendo 1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 121
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Women of at least 18 years of age at the time of signing of informed consent
- •- Diagnosis of endometriosis confirmed by at least one of the two criteria:
- •-- visually-confirmed (by surgery or clinical inspection) within the last 10 years
- •-- imaging-confirmed within the last 12 months
- •- Symptoms of moderate to severe pelvic pain which will be assessed over a period of 28 days
- •- Good general health
- •- Willingness to use only ibuprofen as rescue pain medication for endometriosis-associated pelvic pain
- •- Willingness to use non-hormonal barrier method for contraception (here spermicide-coated condoms) from screening visit until the end of
- •the study (maximum 280 days) and to refrain from using hormonal contraception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Pregnancy or lactation (less than three months since delivery, abortion, or lactation before start of treatment) AND no wish for pregnancy during the study
- •- Altered bilirubin metabolism and liver function at Visit 1
- •- Requirement to use pain medications for reasons other than endometriosis
- •- Contraindications to using ibuprofen and/or contraindications to using the study drug
- •- Signs of hyperandrogenism
- •- Absence of menstrual cycles and/or abnormal vaginal/genital bleeding
- •- History of hysterectomy, tubal-ligation or bilateral ovariectomy
- •- Any diseases, conditions or edications/treatments that might intefere with the conduct of the study or the interpretation of the results
研究者
相似试验
进行中（未招募）
1 期
A study to test whether study drug BAY1128688 brings pain relief to women with endometriosis and if so to get a first idea which dose(s) work best.MedDRA version: 20.0 Level: LLT Classification code 10014788 Term: Endometriosis related pain System Organ Class: 100000024185MedDRA version: 20.0 Level: PT Classification code 10014778 Term: Endometriosis System Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2017-000244-18-NLBayer AG121
进行中（未招募）
1 期
A study to test whether study drug BAY1128688 brings pain relief to women with endometriosis and if so to get a first idea which dose(s) work best.MedDRA version: 20.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2017-000244-18-ATBayer AG120
已完成
不适用
A randomized, placebo-controlled, double-blind, parallel-group trial of the improvement in ocular function with continued lutein intakeHealthy subjectsJPRN-UMIN000033854HUMA R&D CORP62
进行中（未招募）
1 期
A Phase 2a, randomized, placebo-controlled, double-blind study to investigate REM0046127 in mild to moderate Alzheimer's diseaseMedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 100000004852Alzheimer's DiseaseEUCTR2022-000080-43-ESreMYND60
进行中（未招募）
1 期
A study to test whether study drug BAY1128688 brings pain relief to women with endometriosis and if so to get a first idea which dose(s) work best.EndometriosisEUCTR2017-000244-18-CZBayer AG121